TY  - CONF

T1  - The DISPERSE2 trial: Safety, tolerability and preliminary efficacy of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel in patients with non-ST segment elevation acute coronary syndrome

JO  - CIRCULATION

PY  - 2005/10/25

AU  - Cannon CP

AU  - Husted S

AU  - Storey RF

AU  - Harrington RA

AU  - Hill S

AU  - Price D

AU  - Sanders N

AU  - Emanuelsson H

AU  - Peters G

AU  - DISPERSE 2 Investigators

ED  - 

VL  - 112

IS  - 17

SP  - U677

EP  - U677

Y2  - 2024/12/22

ER  -